AVXL (Anavex Life Sciences) Research & Development: $31.80 Mil (TTM As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.56
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Research & Development?

Anavex Life Sciences AVXL -0.97% 30 Research & Development is $31.80 Mil as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Anavex Life Sciences's Research & Development for the three months ended in Dec. 2025 was $4.66 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was $31.80 Mil.

Anavex Life Sciences  (NAS:AVXL) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Anavex Life Sciences Research & Development Related Terms

Anavex Life Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Research & Development Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.98 37.92 43.72 41.84 37.59

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.45 9.89 9.96 7.29 4.66
AVXL
30GF Score
Anavex Life Sciences Corp AVXL
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $31.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $31.80 Mil mean?
Anavex Life Sciences (AVXL) has a Research & Development of $31.80 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' Research & Development too high?
Anavex Life Sciences' current Research & Development is $31.80 Mil. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Research & Development compare to ZNTL and HUMA?
Anavex Life Sciences' Research & Development of $31.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Research & Development is $31.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Research & Development of $31.80 Mil. The current Research & Development is $31.80 Mil. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Research & Development is $31.80 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56
Price